AMAG Pharmaceuticals Announces Patent Term Extension for Ferumoxytol in the U.S.

WALTHAM, Mass., June 6, 2014 (GLOBE NEWSWIRE) — AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) today announced that the United States Patent and Trademark Office (USPTO) has issued a U.S. patent term extension certificate extending the term of U.S. Patent No. 6,599,498 by 1,209 days. With this extension the ‘498 patent will now expire June 30, 2023. This patent is directed to reduced polysaccharide iron oxide complexes, including ferumoxytol. The ‘498 patent is listed in Approved Drug Products with Therapeutic Equivalence Evaluations (commonly known as the Orange Book), published by the United States Food and Drug Administration.

The patent term extension certificate was granted under the patent restoration provisions of the Drug Price Competition and Patent Term Restoration Act of 1984. The patent term certificate extends the term of the ‘498 patent from its original expiration date of 2020.

“This patent extension for ferumoxytol further lengthens our intellectual property protection and enhances the long-term value of a product that generated 28 percent revenue growth in the U.S. in 2013 for our company,” said William Heiden, chief executive officer of AMAG.

AMAG has five Orange Book-listed patents relating to ferumoxytol, including the ‘498 patent.

About AMAG

AMAG Pharmaceuticals, Inc. is a specialty pharmaceutical company that markets Feraheme® (ferumoxytol) Injection and MuGard® Mucoadhesive Oral Wound Rinse in the United States. Along with driving continued growth of its products, AMAG intends to continue to expand its portfolio through the in-license or purchase of additional specialty pharmaceutical products or companies. In particular, the company is seeking complementary products that will leverage its commercial infrastructure and focus on hematology and oncology centers, hospital infusion centers or other sites of care where IV iron is administered. AMAG is also evaluating products in other strategic areas of interest, products that may entail lower-risk late-stage development and transactions that could be financially beneficial to the company, such as those that potentially optimize after-tax cash flows or drive positive earnings. For additional company information, please visit

About Feraheme® (ferumoxytol)/Rienso

In the United States, Feraheme (ferumoxytol) Injection for Intravenous (IV) use is indicated for the treatment of iron deficiency anemia (IDA) in adult patients who have failed oral iron therapy. Feraheme received marketing approval from the FDA on June 30, 2009 for the treatment of IDA in adult chronic kidney disease (CKD) patients and was commercially launched by AMAG in the U.S. shortly thereafter.

Ferumoxytol is protected in the U.S. by five issued patents covering the composition and dosage form of the product. Each issued patent is listed in the FDA’s Orange Book. These patents are set to expire in March 2020, with one patent expiring in June 2023.

Ferumoxytol received marketing approval in Canada in December 2011, where it is marketed by Takeda as Feraheme, and in the European Union in June 2012 and Switzerland in August 2012, where it is marketed by Takeda as Rienso.

For additional U.S. product information, including full prescribing information, please visit

AMAG Pharmaceuticals and Feraheme are registered trademarks of AMAG Pharmaceuticals, Inc. MuGard® is a registered trademark of Access Pharmaceuticals, Inc.

Rienso is a trademark of Takeda Pharmaceutical Company Limited.

CONTACT: AMAG Pharmaceuticals, Inc. Contact:  Katie Payne, 617-498-3303

AMAG Pharmaceuticals logo

AMAG Pharmaceuticals, Inc.